Nelistotug

尼利苏塔单抗

Report date: 2026/05/20 20:02:01

Base Information

Drug NameNelistotug
Drug Alias NameGSK-6097608GSK-608GSK’608 CD96GSK’608
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionT-cell surface protein tactile inhibitorsAntibody-dependent cell-mediated cytotoxicity (ADCC) effects
TargetsT-cell surface protein tactile
Therapy Area/IndicationsHead and Neck NeoplasmsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesTaiwan +[19] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesGlaxosmithkline Plc
China Registration ClassN/A

Develop Information

Active CompaniesGlaxosmithkline Plc
Inactive CompaniesN/A
Active IndicationsHead and Neck Neoplasms
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A